A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication

NCT01131013 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Intermittent Claudication
Peripheral Artery Disease

Interventions

DRUG: Placebo
DRUG: 375 mg CK-2017357
DRUG: 500 mg CK-2017357

Sponsor

Cytokinetics